ARQ 621 NEW
| Price | $56 | $84 | $147 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: ARQ 621 | CAS No.: 1095253-39-6 |
| Purity: 98.38% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | ARQ 621 |
| Description | ARQ 621 is an allosteric, and selective Eg5 mitotic motor protein inhibitor. Phase 1. |
| In vitro | ARQ 621 demonstrates anti-tumor activity against a wide range of human cancer cell lines in vitro, including colon, lung, endometrial, bladder, and hematologic cancer cell lines, with significantly less cytotoxicity against hematopoietic cells. [1] |
| In vivo | ARQ 621, as a novel clinical stage drug candidate, inhibits a number of xenografts grown in athymic mice, such as pancreatic, breast, prostate, and ovarian carcinomas with no hematological changes. Furthermore, for ARQ 621, there is no envidence of bone marrow toxicity in pre-clinical mouse efficacy models or safety studies in rats and dogs. [1] |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 93 mg/mL (168.3 mM) DMSO : 93 mg/mL (168.3 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) |
| Keywords | motor | ARQ 621 | inhibit | cell | division | ARQ621 | protein | Inhibitor | microtubule | Kinesin | Anti-tumor | Eg5 | ARQ-621 |
| Inhibitors Related | Eg5-IN-1 | Eg5 Inhibitor V, trans-24 | AZD-4877 | UMK57 | BAY1217389 | BRD9876 | Paprotrain | SB-743921 hydrochloride | S-trityl-L-Cysteine | Empesertib | MPI-0479605 | CW-069 |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1520.00/25mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $88.00/1EA |
Amikon Limited
|
2018-07-26 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY